| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d7dd974133b517679634e95e4e81115c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9687e41c163cc7bf5fb7ae75330c37e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_88d6ebe0dfa69b2821ddb6461901895c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_165b0c67e68150668efe0f4be7b24a65 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1282
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-40 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-02 |
| filingDate |
2009-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2013-01-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_edf18cf98550d03e24ddeec9e757c373
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af31b059a9050ba1e31840eb5728a227
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fcb71475c059880378f87a19ac1ad762 |
| publicationDate |
2013-01-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8343508-B2 |
| titleOfInvention |
Botulinum antitoxin compositions and methods |
| abstract |
This invention provides botulinum antitoxin compositions and methods of production, and methods of treating animals and humans prophylactically and also those suspected of having contacted botulism toxin. The botulinum antitoxin is prepared by inoculating an animal with a monovalent botulinum toxoid and toxin. The animal's plasma is collected and purified at a high pH by affinity chromatography. The resulting monovalent immunoglobulins are de-speciated by digestion with pepsin. Monovalent antitoxins for all seven botulinum serotypes are then combined to produce a high titered heptavalent botulinum antitoxin composition. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11382960-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9095523-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9572871-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10792344-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014010803-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10973890-B2 |
| priorityDate |
2003-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |